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ABSTRACT 
Osteosarcoma is the most common primary bone tumour in dogs but various forms of therapy 
have not significantly improved clinical outcomes. As dysregulation of kinase activity is 
often present in tumours, kinases represent attractive molecular targets for cancer therapy. 
The purpose of this study was to identify novel compounds targeting kinases with the 
potential to induce cell death in a panel of canine osteosarcoma cell lines. The ability of 80 
well-characterized kinase inhibitor compounds to inhibit the proliferation of four canine 
osteosarcoma cell lines was investigated in vitro. For those compounds with activity, the 
mechanism of action and capability to potentiate the activity of doxorubicin was further 
evaluated. The screening showed 22 different kinase inhibitors that induced significant anti-
proliferative effects across the four canine osteosarcoma cell lines investigated. Four of these 
compounds (RO 31-8220, 5-iodotubercidin, BAY 11-7082 and an erbstatin analog) showed 
significant cell growth inhibitory effects across all cell lines in association with variable 
induction of apoptosis. RO 31-8220 and 5-iodotubercidin showed the highest ability to 
potentiate the effects of doxorubicin on cell viability. In conclusion, the present study 
identified several potent kinase inhibitors targeting the PKC, CK1, PKA, ErbB2, mTOR and 
NF-κB pathways, which may warrant further investigations for the treatment of osteosarcoma 
in dogs. 
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